Evogene Ltd. (TLV:EVGN)
Israel · Delayed Price · Currency is ILS · Price in ILA 318.40
-8.50 (-2.60%)
At close: Jan 30, 2026
Evogene Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 8.02 | 8.51 | 5.64 | 1.68 | 0.93 | 1.04 | |
Revenue Growth (YoY) | 7.19% | 50.90% | 236.72% | 80.11% | -10.58% | 38.11% |
Cost of Revenue | 2.81 | 2.68 | 1.69 | 0.91 | 0.77 | 0.57 |
Gross Profit | 5.21 | 5.83 | 3.95 | 0.77 | 0.16 | 0.47 |
Selling, General & Admin | 8.09 | 10.87 | 9.68 | 10.42 | 9.99 | 7.99 |
Research & Development | 13.01 | 16.65 | 20.78 | 20.79 | 21.13 | 17.29 |
Other Operating Expenses | 0.32 | 0.52 | - | -3.5 | - | - |
Operating Expenses | 21.42 | 28.04 | 30.46 | 27.71 | 31.12 | 25.28 |
Operating Income | -16.21 | -22.21 | -26.51 | -26.94 | -30.95 | -24.81 |
Interest Expense | - | -0.06 | -0.12 | -0.17 | -0.32 | -0.24 |
Interest & Investment Income | 2.09 | 0.96 | 1.25 | 0.18 | 0.29 | 0.23 |
Earnings From Equity Investments | -0.1 | -0.04 | - | - | - | - |
Currency Exchange Gain (Loss) | -0.05 | -0.05 | -0.25 | -1.74 | 1.07 | 1.01 |
Other Non Operating Income (Expenses) | 3.36 | 3.36 | -0.16 | -0.25 | -0.46 | -2.33 |
EBT Excluding Unusual Items | -10.9 | -18.04 | -25.78 | -28.92 | -30.37 | -26.14 |
Gain (Loss) on Sale of Investments | - | - | 0.05 | -0.72 | -0.06 | -0.03 |
Other Unusual Items | -0 | -0 | -0.25 | -0.11 | - | - |
Pretax Income | -10.41 | -18.05 | -25.99 | -29.75 | -30.43 | -26.17 |
Income Tax Expense | 0.01 | 0.01 | -0.03 | 0.09 | 0.01 | 0.03 |
Earnings From Continuing Operations | -10.42 | -18.05 | -25.95 | -29.84 | -30.45 | -26.21 |
Minority Interest in Earnings | -0.27 | 1.57 | 2.08 | 3.21 | 2.65 | 2.83 |
Net Income | -2.75 | -16.49 | -23.88 | -26.64 | -27.79 | -23.37 |
Net Income to Common | -2.75 | -16.49 | -23.88 | -26.64 | -27.79 | -23.37 |
Shares Outstanding (Basic) | 7 | 6 | 5 | 4 | 4 | 3 |
Shares Outstanding (Diluted) | 7 | 6 | 5 | 4 | 4 | 3 |
Shares Change (YoY) | 40.93% | 24.14% | 10.80% | 2.44% | 43.59% | 9.34% |
EPS (Basic) | -0.37 | -2.89 | -5.20 | -6.43 | -6.87 | -8.30 |
EPS (Diluted) | -0.37 | -2.89 | -5.20 | -6.43 | -6.87 | -8.30 |
Free Cash Flow | -15.83 | -20.33 | -22.36 | -24.85 | -25.56 | -20.2 |
Free Cash Flow Per Share | -2.14 | -3.57 | -4.87 | -6.00 | -6.32 | -7.17 |
Gross Margin | 65.01% | 68.48% | 70.00% | 45.73% | 17.53% | 44.81% |
Operating Margin | -202.20% | -260.96% | -470.00% | -1608.42% | -3328.28% | -2385.96% |
Profit Margin | -34.29% | -193.69% | -423.39% | -1590.33% | -2988.49% | -2247.50% |
Free Cash Flow Margin | -197.46% | -238.82% | -396.49% | -1483.52% | -2748.71% | -1941.92% |
EBITDA | -14.56 | -20.5 | -24.7 | -24.36 | -28.72 | -22.09 |
EBITDA Margin | -181.64% | -240.90% | - | - | - | - |
D&A For EBITDA | 1.65 | 1.71 | 1.81 | 2.58 | 2.23 | 2.73 |
EBIT | -16.21 | -22.21 | -26.51 | -26.94 | -30.95 | -24.81 |
EBIT Margin | -202.20% | -260.96% | - | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.